- Home
- GROV vs HOWL Comparison
GROV vs HOWL Comparison
Compare GROV & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROV
- HOWL
- Stock Information
- Founded
- GROV 2016
- HOWL 2017
- Country
- GROV United States
- HOWL United States
- Employees
- GROV N/A
- HOWL N/A
- Industry
- GROV Package Goods/Cosmetics
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- GROV Consumer Discretionary
- HOWL Health Care
- Exchange
- GROV Nasdaq
- HOWL Nasdaq
- Market Cap
- GROV 59.0M
- HOWL 62.4M
- IPO Year
- GROV N/A
- HOWL 2021
- Fundamental
- Price
- GROV $1.66
- HOWL $1.21
- Analyst Decision
- GROV Buy
- HOWL Strong Buy
- Analyst Count
- GROV 1
- HOWL 3
- Target Price
- GROV $2.00
- HOWL $9.00
- AVG Volume (30 Days)
- GROV 86.7K
- HOWL 242.3K
- Earning Date
- GROV 03-11-2025
- HOWL 03-11-2025
- Dividend Yield
- GROV N/A
- HOWL N/A
- EPS Growth
- GROV N/A
- HOWL N/A
- EPS
- GROV N/A
- HOWL N/A
- Revenue
- GROV $213,781,000.00
- HOWL $1,885,000.00
- Revenue This Year
- GROV N/A
- HOWL $36.45
- Revenue Next Year
- GROV $0.84
- HOWL $296.58
- P/E Ratio
- GROV N/A
- HOWL N/A
- Revenue Growth
- GROV N/A
- HOWL N/A
- 52 Week Low
- GROV $1.19
- HOWL $1.03
- 52 Week High
- GROV $2.00
- HOWL $6.89
- Technical
- Relative Strength Index (RSI)
- GROV 57.30
- HOWL 40.43
- Support Level
- GROV $1.55
- HOWL $1.18
- Resistance Level
- GROV $1.65
- HOWL $1.30
- Average True Range (ATR)
- GROV 0.09
- HOWL 0.10
- MACD
- GROV -0.01
- HOWL 0.00
- Stochastic Oscillator
- GROV 75.96
- HOWL 47.37
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.